Ophthalmology has become a "safe haven" for gene therapy because it mitigates the field's two main challenges: safety and manufacturing. Localized delivery to the immune-privileged eye improves the safety profile, while the thousand-fold lower required doses simplify manufacturing and dramatically improve the cost of goods.

Founder Sean Ainsworth intentionally started his pioneering AAV gene therapy in an ocular setting before any Western approvals existed. Because an intravitreal injection uses a very small vector amount, it provided a significant safety advantage and a manageable way to prove the technology before attempting systemic delivery.

CEO Elizabeth Jeffords argues ophthalmology lags behind oncology in treatment philosophy. She applies oncology's core lessons—treat early, use combinations, target precisely, and act locally—to Iolyx's development strategy for immune-driven eye diseases, moving beyond one-size-fits-all approaches.

Iolyx CEO Elizabeth Jeffords insists on commercial input even in preclinical stages. This meant killing an ointment formulation—which patients find 'greasy' and 'disgusting'—in favor of developing a more patient-friendly eyedrop. This avoids creating a product that is clinically sound but has poor real-world adoption.

Despite initial hype in oncology where business models struggled, cell therapy is finding a major new application in treating autoimmune diseases. By resetting the immune system, it can offer functional cures for debilitating conditions—a powerful and unexpected pivot for the technology platform.

The current boom in immunology and autoimmune (I&I) therapeutics is not a separate phenomenon but a direct consequence of capital and knowledge from immuno-oncology. Many of the same biological pathways are being targeted, simply modulated down (for autoimmune) instead of up (for cancer), allowing for rapid therapeutic advancement and platform reuse.

The field of ophthalmology is particularly well-suited for a hub-and-spoke model because it utilizes a wide range of treatment modalities (small molecules, biologics, devices, gene therapy). This allows a central hub to leverage shared expertise in areas like ocular delivery and regulatory pathways across multiple, diverse spokes.

Despite significant progress in managing symptoms for autoimmune conditions, very few treatments fundamentally alter the disease's course. The major unmet needs and investment opportunities lie in therapies that can induce remission or target common underlying pathologies like fibrosis, moving beyond mere symptom relief.

CEO Lance Baldo suggests that gene therapy in the eye is uniquely positioned for success. As an encapsulated organ with "immune privilege," the eye reduces risks like hepatotoxicity seen in systemic therapies. This creates a safer environment to generate learnings that can then be applied to advance gene therapies for other organs.